Titre
Regrese osteolytického loziska u pacienta s mnohocetným myelomem léceného klodronátem po uspesné terapii rezimem s bortezomibem [Regression of an osteolytic lesion in a patient with multiple myeloma treated with clodronate after a successful therapy with bortezomib-based regimen]
Type
article
Institution
Externe
Périodique
Klinicka onkologie
Auteur(s)
Szturz, Petr
Auteure/Auteur
Jakubcová, R.
Auteure/Auteur
Adam, Z.
Auteure/Auteur
Klincová, M.
Auteure/Auteur
Krejcí, M.
Auteure/Auteur
Pour, L.
Auteure/Auteur
Zahradová, L.
Auteure/Auteur
Hájek, R.
Auteure/Auteur
Mayer, J.
Auteure/Auteur
Liens vers les personnes
ISSN
0862-495X
Statut éditorial
Publié
Date de publication
2011
Volume
24
Numéro
3
Première page
216
Dernière page/numéro d’article
220
Peer-reviewed
Oui
Langue
tchèque
Notes
Publication types: Case Reports ; Journal Article
Publication Status: ppublish
Publication Status: ppublish
Résumé
Osteolytic lesions are a common manifestation of multiple myeloma, though their healing is rare in these patients. Generally, during a complete remission, lesions only stop progressing; radiologically evident recalcification is exceptional.
Herein we report a case of a male patient born in 1941 and diagnosed in 2005 with IgA multiple myeloma presenting with multiple osteolytic bone lesions. Administration of 4 cycles of VAD chemotherapy (vincristine, adriamycin, dexamethasone) with subsequent autologous peripheral blood stem cell transplantation and maintenance treatment with interferon alpha had resulted into a very good partial remission. In 2009, the disease relapsed with enlargement of osteolytic lesions evident on skiagrams. The largest lesion, reaching 24 x 10 mm in size, was located in the left femur. A complete remission of the disease was achieved with CVD senior regimen (cyclophosphamide, bortezomib, dexamethasone, 8 cycles in total). Bisphosphonates (zoledronate, ibandronate and, from 2007, clodronate) were administered as a long-term supportive therapy. A one-year follow-up skiagram of the left femur revealed over 50% regression of the osteolytic lesion (10 x 5 mm) documented in a set of pictures herein.
A complete remission of the disease after an administration of bortezomib (Velcade)-based regimen in a long-term clodronate (Bonefos)-treated patient with relapsed multiple myeloma is radiographically apparent by clear healing signs of the osteolytic bone lesion.
Herein we report a case of a male patient born in 1941 and diagnosed in 2005 with IgA multiple myeloma presenting with multiple osteolytic bone lesions. Administration of 4 cycles of VAD chemotherapy (vincristine, adriamycin, dexamethasone) with subsequent autologous peripheral blood stem cell transplantation and maintenance treatment with interferon alpha had resulted into a very good partial remission. In 2009, the disease relapsed with enlargement of osteolytic lesions evident on skiagrams. The largest lesion, reaching 24 x 10 mm in size, was located in the left femur. A complete remission of the disease was achieved with CVD senior regimen (cyclophosphamide, bortezomib, dexamethasone, 8 cycles in total). Bisphosphonates (zoledronate, ibandronate and, from 2007, clodronate) were administered as a long-term supportive therapy. A one-year follow-up skiagram of the left femur revealed over 50% regression of the osteolytic lesion (10 x 5 mm) documented in a set of pictures herein.
A complete remission of the disease after an administration of bortezomib (Velcade)-based regimen in a long-term clodronate (Bonefos)-treated patient with relapsed multiple myeloma is radiographically apparent by clear healing signs of the osteolytic bone lesion.
Sujets
PID Serval
serval:BIB_3C3FAA48E717
PMID
Date de création
2025-01-07T16:11:45.470Z
Date de création dans IRIS
2025-05-20T20:19:57Z